Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Ocular Hypertension
- Registration Number
- NCT00332059
- Lead Sponsor
- Allergan
- Brief Summary
The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 445
Inclusion Criteria
- Clinical diagnosis of glaucoma or ocular hypertension in both eyes
- Patient requires IOP-lowering drug in both eyes
Exclusion Criteria
- Uncontrolled medical conditions
- Contraindication to beta-adrenoceptor antagonist therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method IOP
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of bimatoprost and timolol in reducing intraocular pressure for glaucoma and ocular hypertension?
How does the bimatoprost/timolol fixed combination compare to other prostaglandin analogs and beta-blockers in managing ocular hypertension?
What biomarkers are associated with response to bimatoprost/timolol in patients with primary open-angle glaucoma or ocular hypertension?
What are the potential adverse events and management strategies for bimatoprost/timolol fixed combination in glaucoma treatment?
Are there alternative combination therapies to bimatoprost/timolol for intraocular pressure reduction in patients with ocular hypertension?